Research Project
- Last Updated On :
RESEARCH
FUNDED PROJECTS
Ongoing
|
S.No.
|
Titleofthe project |
NameofPrincipal Investigator |
Fundedby(Name orfundingagency) |
Duration years |
Startyear |
Endyear |
Totalfunds Sanctioned(Rs) |
|
1. |
Regional Virus Research and Diagnostic Laboratory (RL-VRDL) |
Dr. Lalit Dar |
Department of Health Research (DHR) |
10 years (extendable) |
2019 |
Continuous |
~ 5 crore |
|
2. |
External Quality Assurance Scheme (EQAS) of National HIV/AIDS Reference Laboratory, AIIMS, Delhi |
Dr. Bimal Kr. Das |
NACO |
Continuous |
2005 |
Continuous |
Approx. 14 lacs/annum |
|
3. |
HIV integrated counseling and testing (ICTC) |
Dr. Bimal Kr. Das |
NACO |
Continuous |
2005 |
Continuous |
Kits are provided by NACO and the rest is taken care of under EQAS budget |
|
4. |
CD4 testing program |
Dr. Bimal Kr. Das |
NACO |
Continuous |
2005 |
Continuous |
Testing kits provided by NACO, Rs. 50,000/- for Consumables |
|
5 |
Evaluation of NF- κB based reactivation of latency in HIV infected individuals who are on antiretroviral therapy for more than 15 years: A Quest for Cure. |
Dr. Shesh Prakash Maurya (under mentorship of Bimal Kumar Das). |
Funded by DHR (HRD scheme) |
3 years |
2022 |
2025 |
Rs. 50,92,497/- |
|
6 |
Evaluation of role of B-1 cells in modulating the response of T cells in HIV infected patients pre and post antiretroviral therapy: cohort study. |
Dr. Bimal Kumar Das |
Funded by ICMR |
3 years |
2022 |
2025 |
Rs. 50,40,572/- |
|
7 |
Nodal coordinating center for surveillance network of antimicrobial resistance in salmonella enterica serotype Typhi and Paratyphi
|
Dr. Bimal Kumar Das |
Funded by ICMR |
2 YEAR |
2018 |
2024 |
2,39, 22,040 |
|
8 |
Detection of salmonella serovars and their associated resistance marker directly from blood specimen using paper based DNA biosensor |
Dr. Bimal Kumar Das |
Funded by ICMR |
2 YEAR |
2024 |
2026 |
1,35,68,808 |
|
9 |
Proteomics study of Giardia intestinalis isolates to associate with different clinical spectrum and extrapolate its invasive potential |
Dr. B.R Mirdha |
ICMR |
3 years |
Sept, 2023 |
August, 2026 |
48 lakhs |
|
10 |
Characterization of human antibody responses to Plasmodium vivax in India”. (Through Inspire faculty programme) |
Dr. B.R Mirdha |
Department of Science and Technology |
5 years |
August , 2023 |
2028 |
More than 5 Cr. |
|
11 |
ICMRs: Advanced Mycology Diagnostic and Research Centre (AMDRC) |
Prof Immaculata Xess |
ICMR |
5 years |
2022 |
2027 |
250 lakhs |
|
12 |
Multi-centric study on prevalence of Mycoplasma genitalium and its resistance markers in the high–risk group (MSM and FSW) attending sexually transmitted disease cclinics in North India. |
Benu Dhawan |
ICMR |
3 years |
December2021 |
December 2024 |
28.65 Lakhs |
|
13 |
Towards point of care test development for Bacterial Vaginosis, a polymicrobial infection. |
Dr. Seema Sood |
ICMR |
3 years |
2020 |
2023 |
51 Lakhs |
|
14 |
Exploring SELEX technology for potential POCT development for Genital Chlamydia trachomatis. |
Dr. Seema Sood |
ICMR |
3 years |
2022 |
2025 |
50 Lakhs |
|
15 |
Point-of-care test development for Bacterial Vaginosis (BV): Bench to bedside (Clinical validation of proof-of-concept). |
Dr. Seema Sood |
ICMR |
3 years |
2024 |
2027 |
75 Lakhs |
|
16 |
Mapping hotspots of MDR-TB in Assam, Sikkim and Tripura using Genomics approaches |
Dr. Urvashi B. Singh |
DBT-NER |
3 years |
2018 |
2024 |
~ 4 Cr |
|
17 |
Epidemiological impact and intersection of the COVID-19 and Tuberculosis Pandemics in Brazil, Russia, India and South Africa |
Dr. Urvashi B. Singh |
DST |
2 years |
2021 |
2023 |
1.72 Cr |
|
18 |
Validation of Indigenously Developed Diagnostic kit based on Detection of Proteomic markers from Urine for Diagnosis of Pulmonary and Extra-pulmonary Tuberculosis |
Dr. Urvashi B. Singh |
ICMR |
3 years |
2022 |
2025 |
1.4 cr |
|
19 |
Operational Feasibility and performance of indigenous phenotypic kit for detection of multidrug resistant tuberculosis and extensively drug resistant tuberculosis in field setting under the National Tuberculosis Elimination program |
Dr. Urvashi B. Singh |
ICMR |
3 years |
2022 |
2025 |
14 lakhs |
|
20 |
Development of Surface Plasmon Resonance Array Biosensor for Rapid Molecular Drug Resistance Detection for MDR and XDR TB |
Dr. Urvashi B. Singh |
ICMR |
2 years |
2023 |
2025 |
40 Lakhs |
|
21 |
Development of Surface Enhanced Raman Scattering (SERS) Based Biosensor for Rapid Detection of oligonucleotides in MDR and XDR-TB. |
Dr. Urvashi B. Singh |
AIIMS-IITD |
2 years |
2022 |
2024 |
10 Lakhs |
|
22 |
A Preclinical Study to evaluate synergistic action of Rifampicin with Faropenem and Cefdinir on persister Mycobacterium tuberculosis bacilli in mouse model. |
Dr. Urvashi B. Singh |
AIIMS-THSTI |
2 years |
2023 |
2025 |
10 Lakhs |
|
23 |
To determine the prevalence of common virulence determinants associated with Uropathogenic Escherichia coli from community-setting at different geographical regions of India using phenotypic and genotypic methods |
Dr. Sarita Mohapatra |
ICMR |
3 year |
2022 |
2025 |
Rs553400.00 |
|
24 |
Platform for discovery of novel therapeutic monoclonal antibodies against MDR and XDR Klebsiella pneumoniae |
Sarita Mohapatra (Co-PI)/year |
DBT-BIRAC |
3 years |
2023 |
2026 |
Rs. 4,88,840.00 |
|
25 |
Micro-nano structured urinary catheter to minimize catheter-associated urinary tract infection |
Sarita Mohapatra (Co-PI) |
MoE-STARS |
3 years |
2023 |
2026 |
Rs 32.6 lacs |
|
26 |
National Program for the Surveillance of Viral Hepatitis
|
Dr. Aashish Choudhary |
Ministry of Health & Family Welfare (MoHFW) |
5 years (extendable) |
2020 |
Continuous |
~ 1.3 crore |
|
27 |
NACO Regional Reference Laboratory for HIV viral load (VL) |
Dr. Aashish Choudhary |
National AIDS Control Organization (NACO) |
No fixed duration |
2019 |
Continuous |
~ 51 lakhs
|
|
28 |
NACO Regional Reference Laboratory for HIV early infant diagnosis (EID) |
Dr. Aashish Choudhary |
National AIDS Control Organization (NACO) |
No fixed duration |
2012 |
Continuous |
~ 93 lakhs |
|
29 |
Whole genome sequencing of the SARS-CoV-2 novel coronavirus strains at a tertiary care center in Delhi. |
Dr. Aashish Choudhary |
AIIMS Delhi (Intramural grant) |
2 years |
2020 |
2023 |
~ 11 lakhs |
|
30 |
Molecular Epidemiology and In-Vitro Antifungal Susceptibility of Cryptic Aspergillus species from Clinical and Environment samples |
Dr. Gagandeep Singh |
ICMR |
3 years |
2022 |
2025 |
35 lakhs |
|
31 |
Genomic profiling of invasive and hospital acquired Escherichia coli pathotypes from different clinical samples to identify the virulence and antimicrobial resistance markers |
Dr. Hitender Gautam |
Science & Engineering Research Board SERB (Under DST) |
2 years 6 months |
Mar 2022 |
Sept 2024 |
45,45,816/- |
|
32 |
Site-specific biomarkers to differentiate infection from either colonization or aseptic inflammation in ICU |
Dr. Hitender Gautam |
ICMR |
3 years |
Jan 2023 |
Dec 2025 |
73,39,362/- |
|
33 |
Molecular Characterization of diarrheagenic Escherichia coli among children with acute diarrhea: Association of virulence and adherence genes. |
AIIMS Site PI: Dr. Hitender Gautam |
Department of Health Research (DHR) |
3 years |
Jan 2024 |
Dec 2026 |
20,42,367/- |
|
34 |
PlatPlatform for enhanced pathogen detection for meningitis and sepsis: Rapid, portable, and field-deployable diagnostics. IIRPIG-2023-0001405 |
AIIMS Site PI: Dr. Hitender Gautam |
ICMR |
4 years |
Mar 2024 |
Feb 2027 |
93,46,030/- |
|
35 |
Detection of viable but non-culturable (VBNC) Gram-negative bacteria in sepsis and meningitis: Clinical significance in AMR stewardship |
AIIMS Site PI: Dr. Hitender Gautam |
AIIMS-THSTI Collaborative Project |
2 years |
Dec 2023 |
Dec 2025 |
10 Lakhs |
|
36 |
Antimicrobial susceptibility patterns of pathogens isolated in bloodstream infections vis a vis antibiotic prescribing practices and genotypic clonality of Acinetobacter baumannii in various patient care units/areas |
Dr. Hitender Gautam |
Inter-Disciplinary AIIMS IMRG. |
1 year |
Jan 2024 |
Jan 2025 |
4,90,350/- |
|
37 |
Clinical and epidemiological study of Lyme disease: a multi-centric taskforce study in India |
Dr. Nishant Verma |
ICMR |
3 |
2020 |
2023 |
3,86,71,240/- |
|
38 |
Proteomics study of Giardia intestinalis isolates to associate with different clinical spectrum and extrapolate its invasive potential |
Dr. Nishant Verma |
ICMR |
3 |
2023 |
2026 |
48,69,222 |
|
39 |
Expanded viral etiological investigation of genital ulcer disease with phenotyping and genotyping for antiviral drug resistance in herpes simplex viruses |
Dr. Megha Brijwal |
ICMR |
3 years |
2023 |
2026 |
~ 59 lakhs |
|
40 |
Strengthening Capacity for Genomic Sequencing of Outbreak Prone Respiratory Pathogens like Influenza and Other Respiratory Viruses |
Dr. Megha Brijwal |
CDC & APHL, USA |
5 months |
2023 |
2023 |
~ 40 lakhs |
|
41 |
Quantification of JC polyomavirus in CSF in patients with suspected progressive multifocal leukoencephalopathy (PML) by digital PCR |
Dr. Megha Brijwal |
AIIMS Delhi (Intramural grant) |
1 year |
2023 |
2024 |
~ 5 lakhs |
|
42 |
Non-tubercular mycobacteria responsible for pulmonary disease and infections in procedures involving prosthetic devices, laparoscopy or following other interventions. |
Dr. Kiran Bala |
AIIMS, Intramural |
1 year |
2023 |
2024 |
4.95 Lakhs |
|
43 |
Detection of Mycoplasma pneumoniae infections in acute exacerbation of Chronic Obstructive Pulmonary Disease |
Dr. Tanu Sagar |
AIIMS Intramural |
2 years |
2024 |
2026 |
9.8 Lakhs |
Completed
|
S.No. |
Titleofthe project |
NameofPrincipal Investigator |
Fundedby (Name offundingagency) |
Duration (years) |
Startyear |
Endyear |
Totalfunds sanctioned(Rs) |
|
1 |
Comparison of diagnostic accuracy of Real time PCR versus Nugent’s scoring in Indian women with and without Bacterial Vaginosis (BV). Award of SRFship |
Dr. Seema Sood |
ICMR |
3 years |
2019 |
2022 |
16.6 Lakhs |
|
2 |
Early Bactericidal Activity (EBA) of Rifampicin and Feropenem in Tuberculosis (Rifampicin Susceptible)- |
Dr. Urvashi B. Singh |
ICMR |
2 Years |
2019 |
2022 |
70 Lakhs |
|
3 |
Early Bactericidal Activity (EBA) and Pk/Pd Study of Rifampicin Feropenem Cefdinir with Clavulanate vs Standard of Care in Newly Diagnosed Smear Positive Rifampicin Susceptible TB |
Dr. Urvashi B. Singh |
ICMR |
2 Years |
2019 |
2023 |
70 Lakhs |
|
4 |
Rapid Molecular Drug Resistance Detections for MDR and XDR-TB and Molecular Typing of Mycobacterium Tuberculosis From Ziehl-Neelsen’s Stained Microscopic Slides From Delhi State. |
Dr. Urvashi B. Singh |
ICMR |
3 Years |
2018 |
2022 |
~ 60 Lakhs |
|
5 |
Diagnosis of Pulmonary And Extra-Pulmonary Tuberculosis Patients Using Differentially Expressed Proteins As Potential Biomarkers: An Approach Towards Development Of Point Of Care Test. |
Dr. Urvashi B. Singh |
ICMR |
3 Years |
2018 |
2022 |
60 lakhs |
|
6 |
Crohn’s Disease in India: A multicenter study from a country where intestinal tuberculosis as well as Johne’s disease is endemic. |
Dr. Urvashi B. Singh |
ICMR/DHR |
5 Years |
2016 |
2022 |
35 lacs |
|
7 |
In vitro susceptibility of Cefiderocol against carbapenem-resistant gram-negative bacilli from patients with blood stream infection/sepsis, urinary tract infection or pneumonia |
Dr. Sarita Mohapatra |
Funded (Intramural) |
2yr |
2021 |
2023 |
9.7lacs |
|
8 |
Implementation of An Institutional Antifungal Stewardship Program (AFSP) On The Appropriate Use Of Antifungal Therapy And Outcomes In Patients With Invasive Fungal Infections. |
Dr. Gagandeep Singh |
ICMR |
3 years |
2020 |
2023 |
48 lakhs |
|
9 |
Study of hyaline non-sporulating moulds isolated from clinical samples of tertiary care respiratory hospital in Delhi |
Dr. Gagandeep Singh |
ICMR |
3 years |
2021 |
2024 |
27 lakhs |
|
10 |
Magnitude of asymptomatic malaria infections in pregnant women in a community hospital |
Dr. Nishant Verma |
AIIMS, New Delhi |
1 |
2018
|
2019 (work continued in previous year too) |
4,98,000/- |
|
11 |
A prospective study of viral infections in hematopoietic stem cell transplant recipients at a tertiary care hospital in India |
Dr. Megha Brijwal |
ICMR |
3 years |
2019 |
2023 |
45 lakhs |
|
12 |
Point of care Urinary Lipoarabinomannan antigen (LAM) detection as a diagnostic tool for Extra-pulmonary tuberculosis. |
Dr. Kiran Bala |
AIIMS, Intramural |
2 year |
2021 |
2023 |
4.94 Lakhs |
|
13 |
Changing epidemiology of tuberculosis among SARS CoV-2 pandemics. |
Dr. Kiran Bala |
AIIMS, Intramural |
2 year |
2021 |
2023 |
7.14 Lakhs |
